Table 3.

Response assessment of trabectedin plus PLD

Best response (unconfirmed)	Evaluable patients (n = 77) n (%)
Complete response (CR)	5 (6.5)
Partial response (PR)	19 (24.7)
Stable disease (SD)	16 (20.8)
Progressive disease (PD)	9 (11.7)
Not evaluable	1 (1.3)
Missing	27 (35.1)
Objective response rate (ORR; CR + PR) [95% confidence interval]	14 (31.2) [21.1–42.7]
Disease control rate (DCR; ORR + SD) [95% confidence interval]	40 (52.0) [40.3–63.5]
Duration of response (DOR)a; months [95% confidence interval]	6.25 [3.36–9.44]

^aAssessed on 24 patients